Does Medicare Cover Ozempic?

A patient walks into a pharmacy in Tampa expecting to pick up her first month of Ozempic. The pharmacy tech rings it up. Her copay: $912. She thought it would be $40.

What happened is one of the most common Medicare misunderstandings of the past three years. Her doctor prescribed Ozempic. Her Medicare Part D plan technically covers Ozempic. But somewhere between the prescription pad and the cash register, the diagnosis code on her prescription said obesity instead of type 2 diabetes — and that single difference flipped the drug from covered to excluded.

Ozempic is one of those rare drugs where the same medication, in the same syringe, with the same active ingredient, is covered or not covered based entirely on why your doctor prescribed it. To get this right, you need to understand the rule, the carve-out, and the workaround.

The rule: Ozempic is covered for type 2 diabetes

Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist manufactured by Novo Nordisk. The FDA approved it in 2017 for one indication: improving blood sugar control in adults with type 2 diabetes. It also has a secondary approved use for reducing the risk of major cardiovascular events (heart attack, stroke) in adults with both type 2 diabetes and known heart disease.

When prescribed for type 2 diabetes, Ozempic is covered under Medicare Part D. Almost every standalone prescription drug plan and Medicare Advantage plan with drug coverage includes Ozempic on its formulary, typically on Tier 3 (the preferred-brand tier).

What Tier 3 means for you depends on your specific plan. Standard 2026 plans will usually charge somewhere between $40 and $100 per month copay for a Tier 3 drug, with the exact figure varying by carrier, region, and pharmacy choice. Preferred pharmacies almost always run cheaper than standard ones — sometimes $20 to $30 less per fill, which adds up quickly on a year-round prescription.

There’s one piece of recent good news: as of 2025, Medicare Part D enrollees have an annual out-of-pocket spending cap of $2,000. That cap, created by the Inflation Reduction Act, means that even if your Ozempic copays add up fast, you cannot spend more than $2,000 out of pocket on covered Part D drugs in a calendar year. Hit the cap, and you pay $0 for the rest of the year. For diabetics on Ozempic — often combined with insulin and other Tier 3 medications — many will hit that cap by April or May.

The carve-out: Medicare doesn’t cover weight-loss drugs

Now the wrinkle. Ozempic, like Mounjaro, has become famous less for blood sugar control than for what it does to body weight. People lose 10 to 20 percent of their starting weight on it. Doctors have been prescribing it off-label for weight loss for years, and Novo Nordisk eventually launched a higher-dose version under a different name — Wegovy — that’s specifically FDA-approved for chronic weight management.

Here’s where it matters for Medicare:

A 2003 federal law, the Medicare Modernization Act, created Part D and explicitly excluded a list of drug categories from coverage. One of those excluded categories is “agents when used for anorexia, weight loss, or weight gain.” That clause was written with old-school amphetamine-based diet pills in mind, but the language is broad and Medicare has applied it to GLP-1s when prescribed for weight loss.

That’s why if your doctor writes Ozempic for weight management — even with a legitimate clinical reason like obesity-related joint problems or sleep apnea — your Part D plan can refuse the claim. The drug is the same. The pharmacy will just charge you the cash price, which currently runs about $1,000 per month at most retail pharmacies.

There has been one significant shift here: in March 2024, CMS issued guidance allowing Part D plans to cover Wegovy when it’s prescribed specifically for cardiovascular risk reduction in patients who already have established cardiovascular disease and overweight or obesity. That guidance applies to Wegovy, not Ozempic, and only for that narrow cardiovascular indication. Ozempic itself remains a diabetes drug under Medicare.

What you’ll actually pay

Run the numbers like a worst-case-first exercise.

If you’re on a Medicare Advantage plan or standalone Part D plan and Ozempic is on Tier 3 (which it almost always is), here’s what to expect in 2026:

• Deductible phase: If your plan has a deductible — most do, capped at $590 in 2026 — you’ll pay full negotiated price for Ozempic until you’ve met it. That’s typically around $700 to $900 for one fill at the negotiated Part D rate.
• Initial coverage phase: After the deductible, your Tier 3 copay kicks in. On most standalone PDPs this is $40 to $100; some Advantage plans run lower, particularly at preferred pharmacies.
• Catastrophic phase: Once your true out-of-pocket reaches $2,000, you pay $0 for the rest of the year. This is new as of 2025 and a meaningful change for high-cost specialty users.

The structure rewards staying with your plan all year. If you switch carriers in November or hop to a new plan during open enrollment, your $2,000 counter resets each January 1.

What about Wegovy, Mounjaro, and Zepbound?

The picture across this drug class is best understood as four drugs in a 2x2 grid:

Same companies, same mechanisms, very different coverage outcomes. If you’re shopping plans during open enrollment, the formulary detail page on Medicare.gov will show you the exact tier and any utilization restrictions for each. We have separate breakdowns for Wegovy coverage and Mounjaro coverage that walk through their specific situations.

Restrictions and prior authorization

Even when Ozempic is covered for diabetes, expect some hoops:

• Prior authorization: Most Part D plans require it. Your prescriber’s office will need to submit a form documenting your type 2 diabetes diagnosis (often with A1c results) before the plan will approve the claim.
• Step therapy: Some plans require you to try Metformin first, sometimes a second oral diabetes drug, before they’ll cover a GLP-1 like Ozempic. If you’ve already failed Metformin or it’s contraindicated for you, your prescriber needs to document that.
• Quantity limits: Plans typically limit Ozempic to a 30-day or 90-day supply per fill. Stocking up isn’t an option.

If a prior authorization comes back denied, the appeal pathway is real and works often. Your doctor’s office can submit a formal appeal with additional clinical documentation. CMS publishes data showing that a meaningful share of these appeals succeed when the underlying diagnosis is well-documented.

How to confirm coverage before you fill the prescription

Three steps that’ll save you a $900 surprise at the counter:

1. Pull up your plan’s formulary. Either on the carrier’s site or on medicare.gov/plan-compare, search for “semaglutide” or “Ozempic.” Confirm tier placement and any restrictions (PA, ST, QL flags).
2. Confirm the diagnosis on the prescription. Ask your prescriber to verify the diagnosis code submitted with the claim is for type 2 diabetes (E11.x family in ICD-10). If you’ve recently been re-coded — say, after weight loss — get this clarified before the script goes out.
3. Run a test claim through the pharmacy. Most pharmacies can process a “test bill” that returns the actual copay without dispensing the drug. Ask for one.

If your plan declines and you believe the denial is wrong, your plan must give you a written explanation and an appeal pathway. Appeal in writing with your prescriber’s clinical notes attached. Don’t pay cash and walk away assuming the denial was correct — billing errors and miscoded prescriptions are common reasons for incorrect denials at the pharmacy counter.

The bottom line

Ozempic is covered by Medicare when it’s prescribed and coded for type 2 diabetes. It’s not covered for weight loss, full stop. The drug-and-diagnosis coupling is unusually strict for a drug this expensive, which is why this single question — Does Medicare cover Ozempic? — is asked thousands of times every month and gets answered wrong nearly as often.

Before you start the prescription, talk through three things with your doctor: the diagnosis being submitted, your plan’s prior authorization requirements, and whether step therapy applies. Get those right and the answer becomes simple. Get one wrong and you’re in line for a $912 bill you didn’t see coming.